After implantation during a minimally invasive outpatient procedure, the SetPoint device is programmed to automatically administer therapy on a predetermined schedule for up to 10 years, simplifying care for people living with RA.

The post FDA Approves Neuroimmune Modulation Device for Rheumatoid Arthritis appeared first on Healthcare Communications Network.